Complex Innovative Design
Decentralized Clinical Trials
European Medicines Agency
Hybrid Clinical Trials
In-Vitro Diagnostic Regulation
Outsourcing Clinical Trials
Real-World Evidence (RWE)
Research & Development
Research and Development
RWE Decision Alert
Latest from Alira Health
Execution: How Biotechs Can Plan and Run Successful Clinical Trials
Biotech experts Joris Pezzini and Chris Rao answer questions about the challenges of executing a successful clinical trial.
Mandatory Patient-Focused Listening Sessions with CMS: What Manufacturers Need to Know
To learn about patient-focused listening sessions, their potential impact, and how manufacturers can prepare, we spoke with our experts.
What EU Companies Need to Know about the U.S. Inflation Reduction Act
We spoke with our inhouse experts to learn about the significance of the US Inflation Reduction Act for EU pharma and biotech companies.
We are excited to attend, speak at, and sponsor BioSpain, one of the leading conferences in the European biotechnology field.
12th EPP Life Sciences Pricing Forum
We are excited to speak at the 12th EPP Life Sciences Pricing Forum for pricing directors and executives in Life Sciences.
European Statistical Forum
We'll be at European Statistical Forum to discuss how to optimize sample sizes and time to decision using innovative trial designs.
Alira Health Partners With Col·legi de Metges de Barcelona
We are pleased to partner with Col·legi de Metges de Barcelona (CoMB), an institution that represents and serves the almost 39,000 physicians in Barcelona.
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
Diabetes Management Devices Market Trends 2023 is Released
Alira Health announced today the publication of the Diabetes Management Devices Market Trends 2023, in collaboration with MassMEDIC, the Massachusetts Medical Device Industry Council.
Essential Elements of Technology Transfer
Peter Alexander, Senior Consultant, CMC, co-authored an article about technology transfer categories, essential elements, and documentation.
Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates
Our expert CMC team addresses the manufacturing challenges of ADCs in “Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates.”
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
The NICE recommended routine funding for TRANSLARNA (ataluren) to treat Duchenne Muscular Dystrophy (DMD), based on RWE combined with feedback from patients, caregivers, and clinicians.